Atlanta, GA– Metastatix, Inc., an emerging pharmaceutical company focused on the development of small molecule therapeutics, announced today it has secured $35 million
in Series B financing. The new round of funding primarily will be used to conduct clinical trials of the company’s lead candidate, MSX-122, in cancer patients and to advance the company’s
development programs in inflammation and HIV infection.
Leading this Series B financing is Frazier Healthcare Ventures, one of the nation’s leading providers of venture and growth equity capital to emerging healthcare companies. In this round of
financing, Frazier Healthcare is joined by existing Metastatix investors, including H.I.G. Ventures, The Aurora Funds, CM Capital, SR One, MedImmune Ventures, Georgia Venture Partners,
Centrosome Ventures and the State of Georgia. As a result of this financing, James N. Topper, M.D., Ph.D., General Partner of Frazier Healthcare Ventures, will join the Metastatix Board of
Directors.
“We have been extremely impressed by the caliber of the programs and the team at Metastatix. We are pleased to have led this round, which will provide the capital to transition Metastatix to a clinical-stage pharmaceutical company, with several compelling programs in cancer, infectious disease, and inflammation,” states Dr. Topper of Frazier Healthcare.

“We are both pleased and fortunate to have such a strong group of investors,” said Tony Shuker, Ph.D., President and Chief Executive Officer of Metastatix. “It is very gratifying to retain the
investors who have been with us since our start-up two years ago, as well as those that participated in our Series A financing round. They have proven their value time and again with insight and advice. To have an industry leader like Frazier Healthcare take the lead in this Series B round confirms that the therapeutics we are developing satisfy unmet medical needs and have a high potential value. Dr. Topper will bring a wealth of experience and knowledge to our operations and we look forward to his strong leadership helping Metastatix to achieve its goals.”

“Metastatix has made tremendous progress in a short period of time and we are very pleased to welcome Dr. Topper to the board,” said Dr. Bruce Robertson, Chairman of the Board for
Metastatix and H.I.G. Ventures Managing Director. “This financing will enable us to take the company to the next level in clinical trials in the novel area of CXCR4 inhibition.”

Using technology licensed from Emory University, combined with world-class expertise in medicinal chemistry, Metastatix is developing a robust portfolio of chemical compounds that block
the CXCR4 receptor. These compounds have shown efficacy in validated pre-clinical models of cancer, inflammation, and T-tropic HIV infection. This groundbreaking technology was developed by Emory chemist, Dr. Dennis Liotta, one of the foremost experts in small-molecule drug design.

http://www.metastatix.com/news/Metastatix%20Round%20B%20Release%20100907%20-%20FINAL.pdf